1. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323, 1239–1242 (2020).
2. Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (2021) doi:10.1126/science.abf4063.
3. Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun 12, 1162 (2021).
4. Zuo, J. et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol 22, 620–626 (2021).
5. Park, A. & Iwasaki, A. Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host & Microbe 27, 870–878 (2020).
6. Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science (2020) doi:10.1126/science.abc6261.
7. Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med 26, 1070–1076 (2020).
8. Abers, M. S. et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 6, 144455 (2021).
9. Liu, C. et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell 184, 1836-1857.e22 (2021).
10. Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463–469 (2020).
11. Schulte-Schrepping, J. et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell 182, 1419-1440.e23 (2020).
12. Wilk, A. J. et al. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. J Exp Med 218, e20210582 (2021).
13. Stephenson, E. et al. Single-cell multi-omics analysis of the immune response in COVID-19. Nat Med 27, 904–916 (2021).
14. Talla, A. et al. Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence. bioRxiv 2021.05.26.442666 (2021) doi:10.1101/2021.05.26.442666.
15. Rodda, L. B. et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell 184, 169-183.e17 (2021).
16. Wu, J. et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun 12, 1813 (2021).
17. Crawford, K. H. D. et al. Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. The Journal of Infectious Diseases 223, 197–205 (2021).
18. Chakraborty, S. et al. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine (2022) doi:10.1126/scitranslmed.abm7853.
19. Skowronski, D. M. & De Serres, G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 384, 1576–1577 (2021).
20. Goldberg, Y. et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med 385, e85 (2021).
21. Jagannathan, P. et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun 12, 1967 (2021).
22. Chakraborty, S. et al. Structurally and functionally distinct early antibody responses predict COVID-19 disease trajectory and mRNA vaccine response. bioRxiv 2021.05.25.445649 (2021) doi:10.1101/2021.05.25.445649.
23. Li, S. et al. Molecular signatures of antibody responses derived from a systems biological study of 5 human vaccines. Nat Immunol 15, 195–204 (2014).
24. Mh, L. et al. CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection. Journal of leukocyte biology 99, (2016).
25. Py, L. et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. The American journal of pathology 175, (2009).
26. Moll, H. P., Maier, T., Zommer, A., Lavoie, T. & Brostjan, C. The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types. Cytokine 53, 52–59 (2011).
27. Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18, 220 (2017).
28. Goyal, P. et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med 382, 2372–2374 (2020).
29. Matsumiya, T. & Stafforini, D. M. Function and regulation of retinoic acid-inducible gene-I. Crit Rev Immunol 30, 489–513 (2010).
30. Thomas, D. A., Du, C., Xu, M., Wang, X. & Ley, T. J. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 12, 621–632 (2000).
31. Zhang, J. H. & Xu, M. DNA fragmentation in apoptosis. Cell Res 10, 205–211 (2000).
32. Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410–416 (2021).
33. Uhlén, M. et al. Tissue-based map of the human proteome. Science (2015) doi:10.1126/science.1260419.
34. Jovic, S. et al. The neutrophil-recruiting chemokine GCP-2/CXCL6 is expressed in cystic fibrosis airways and retains its functional properties after binding to extracellular DNA. Mucosal Immunol 9, 112–123 (2016).
35. Sawant, K. V. et al. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci Rep 6, 33123 (2016).
36. Renshaw, S. A. et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 170, 1027–1033 (2003).
37. Patel, H. et al. Proteomic blood profiling in mild, severe and critical COVID-19 patients. Sci Rep 11, 6357 (2021).
38. Yang, Y. et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol 146, 119-127.e4 (2020).
39. Zhang, Q. et al. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation. Med (N Y) 1, 14–20 (2020).
40. Yamada, T. et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat Immunol 22, 820–828 (2021).
41. Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2021).
42. Pamer, E. G. Tipping the balance in favor of protective immunity during influenza virus infection. Proc Natl Acad Sci U S A 106, 4961–4962 (2009).
43. Lim, J. K. et al. Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol 186, 471–478 (2011).
44. Kurihara, T., Warr, G., Loy, J. & Bravo, R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med 186, 1757–1762 (1997).
45. Syedbasha, M. & Egli, A. Interferon Lambda: Modulating Immunity in Infectious Diseases. Front Immunol 8, 119 (2017).
46. To, K. K.-W. et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clin Infect Dis 73, e2946–e2951 (2021).
47. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 70, 792–793 (2021).
48. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34, 525–527 (2016).
49. Korotkevich, G. et al. Fast gene set enrichment analysis. 060012 https://www.biorxiv.org/content/10.1101/060012v3 (2021) doi:10.1101/060012.
50. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 57, 289–300 (1995).